Treatment with cisplatin concomitantly with radiotherapy for head and neck squamous cell carcinoma
Version 1.0
Anbefalinger (centrale budskaber)
Indikation
Indikationen for konkomitant kemoradioterapi med cisplatin er udstukket af den Danske Hoved-Hals Cancer Gruppe, DAHANCA, og beskrevet i de kliniske retningslinjer publiceret på www.dahanca.oncology.dk.
Indikationerne omfatter nasopharynxcancer, lokal-avanceret planocellulært karcinom i mundhule, oropharynx, hypopharynx og larynx samt ved primærbehandling af patienter med ukendt primærtumor og halsmetastaser (A).
Tilsvarende, men med lavere evidensstyrke (B) gives cisplatin ved planocellulær sinonasal cancer med stor tumorbyrde og ved postoperativ strålebehandling ved tumorer med høj risiko for tilbagefald (ikke radikal operation) eller gennemvækst af lymfeknude) (B).
Behandling
Konkomitant cisplatin 40 mg/m2 bør gives 5 eller 6 gange med en uges mellemrum under strålebehandling på de af DAHANCA givne indikationer (www.dahanca.oncology.dk) (B)
Første behandling bør gives på første strålebehandlingsdag, men kan gives indenfor den første uge. Behandling kan gives ambulant, 3-4 timer før strålebehandling (C).
Understøttende behandling
Hydrering med intravenøs isotonisk saltvand skal gives før og efter cisplatininfusion (se skema A, appendix) (A).
Intravenøs mannitol kan gives før cisplatininfusion mhp. beskyttelse af nyrerne (se skema A, appendix) (B).
Magnesium skal gives i forbindelse med cisplatininfusion (se skema A, appendix) (A).
Magnesium skal gives i forbindelse med cisplatininfusion (se skema A, appendix) (A).
Screening før behandling
Audiometri bør foretages før første cisplatinbehandling og bør gentages ved tinnitus eller høretab (B).
Nyrefunktionen skal undersøges før første cisplatinbehandling, enten ved at måle glomerulær filtrationshastighed (GFR) med 51Cr-EDTA eller tilsvarende tracer (f.eks. Technetium-99m DTPA) eller ved at beregne estimeret GFR (eGFR) ud fra kreatinin (A).
Før hver cisplatinbehandling skal blodprøver undersøges for knoglemarvssuppression, elektrolytforstyrrelser (Na+, K+, Mg++) og nyrefunktion (A).
Kontraindikationer
Cisplatin bør ikke gives til følgende patienter:
Patienter med nedsat nyrefunktion (GFR < 50 ml/min) eller nyresygdom (A).
Knoglemarvsinsufficiens (B).
Kvinder gravide i første trimester (B).
Patienter, der af lægen vurderes uegnede, f.eks. grundet almentilstand (B).
Cisplatin skal overvejes nøje hos:
English summary
Indications
Indications for cisplatin concomitantly with raditherapy are defined by the Danish Head and Neck Cancer Group, DAHANCA, and described in clinical guidelines published at www.dahanca.oncology.dk.
Indications include nasopharyngeal cancer, locally advanced squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx, as well as for primary treatment of carcinoma of unkown origin with neck node metastases (A).
Likewise, but with a lower level of evidence (B), cisplatin is indicated in squamous cell sinonasal cancer with extensive tumor burden and in postoperative settings with high risk of recurrent disease (incomplete tumor resection) or with extranodal extension.
Treatment
Concomitant cisplatin 40 mg/m2 should be given weekly for 5 or 6 cycles during radiation treatment as described by DAHANCA (www.dahanca.oncology.dk) (B).
The first cycle should be given on the first day of radiotherapy, but may be given within the first week of treatment. Cisplatin may be given as outpatient treatment when possible, and 3-4 hours prior to radiotherapy (C).
Supportive treatment
Intravenous isotonic saline must be administered before and after cisplatin treatment (see Chart A, appendix) (A).
Intravenous mannitol may be administered prior to cisplatin infusion adding to the renal protective effect (see Chart A, appendix) (B).
Magnesium must be administered during cisplatin treatment to reduce the risk of hypomagnesemia (see Chart A, appendix) (A).
Prophylactic anti-emetics should be given according to local guidelines, preferably in accordance with MASCC recommendations (A).
Screening prior to treatment
Audiometry should be performed prior to the first cisplatin treatment and should be repeated if the patient experiences either tinnitus or hearing loss (B).
Renal function must be assessed prior to the first cisplatin treatment, either by measuring glomerular filtration rate (GFR) using 51Cr-EDTA or equivalent radioactive tracers (such as Technetium-99m DTPA) or by using the estimated GFR from blood samples (A).
Before each cisplatin treatment, blood samples must be drawn and assessed for bone marrow suppression, electrolyte imbalance (i.e. Na+, K+, Mg++), and renal function (A).
Contraindications
Cisplatin should not be administered to the following patients:
Patients with reduced renal function (e.g. measured by an estimated by eGFR < 50 ml/min) or pre-existing renal disease (A).
Insufficient bone marrow function (B).
Women pregnant in the first trimester (B)
Patients deemed unfit by the physician, e.g. poor performance status (B).
Cisplatin should be considered carefully in:
Forsæt til hele retningslinjen
Forfattere og habilitet
Camilla K. Lonkvist, MD, PhD, Department of Oncology, Herlev Hospital.
No conflicts of interest.
Jens Bentzen, Senior Consultant, MD, Department of Oncology, Herlev Hospital.
No conflicts of interest.
Jørgen Johansen, Associate Professor, Senior Consultant, MD, Department of Oncology, Odense University Hospital, Odense, Denmark.
No conflicts of interest.